Fármacos utilizados no tratamento de hipercolesterolemia: uma análise histórica e químico-medicinal / Drugs used in the treatment of hypercholesterolemia: a historical and medicinal chemistry focused analysis

Isaac Santiago Cedraz, Stefânia Neiva Lavorato

Abstract


Nesse trabalho, são apresentados aspectos relacionados ao desenvolvimento das principais classes farmacológicas utilizadas no tratamento de hipercolesterolemia, explorando-se as características estruturais importantes a sua ação biológica.


Keywords


hipercolesterolemia, estatinas, ezetimibe, sequestradores de ácidos biliares

References


Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G et al. Niemann–Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption. Science. 303: 1201–1204, 2004.

Ballantyne C. Clinical Lipidology: A companion to Braunwald’s heart disease. 2. ed. Filadelfia: Sauders, 2014.

Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Chron’s disease: A randomized, double-blind, placebo-controlled study. J Chron’s Colitis. 8(11): 1471-1479, 2014.

Bergen SS, Van Itallie TB, Tennent DM, Sebrell WH. Effects of an anion exchange resin on serum cholesterol in man. Proc Soc Exp Biol Med. 102: 676-679, 1959.

Bruckert E. New lipid-modifying therapies. Expert Opin. Investig. Drugs. 12: 325-335, 2003.

Burnett DA, Caplen MA, Davis HR, Burrier RE, Clader JW. 2-Azetidones as inhibitors of cholesterol absorption. J. Med. Chem. 37: 1733-1736, 1994.

Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J. Cardiol. 9(2): 76-91, 2017.

Clader JW. The Discovery of Ezetimibe: A view from outside the receptor. J. Med. Chem. 47(1): 1-9, 2004.

Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S et al. Substituted (1,2-diarylethyl) amide acyl-CoA: cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J. Med. Chem. 38: 1600-1607, 1995.

Davidson MH, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymetric cholesterol-lowering agent. Exp Opin Invest Drugs. 9(11): 2663-2671, 2000.

Dugar S, Yumibe N, Clader JW, Vizziano M, Huie K, Van Heek M et al. Metabolism and structure activity data based drug design: discovery of (-) SCH 53079 an analog of the potent cholesterol absorption inhibitor (-) SCH 48461. Bioorg. Med. Chem. Lett. 6: 1271–1274, 1996.

Elguindy A, Yacounb MH. The discovery of PCSK9 inhibitors: a tale of creativity and multifaceted translational research. Glob. Cardiol. Sci. Pract. 2013(4): 343-347, 2013.

Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium Citrinum. J. Antibiot. 29(12): 1346-1348, 1976.

Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33: 1569-1582, 1992.

Endo A. The origin of the statins. Int Congr. 1262: 3-8, 2004.

Evans M, Roberts A, Rees A. Pharmacological management of hyperlipidemia. Br. J. Diabetes Vasc. Dis. 3: 204-210, 2003.

Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther. 23(6): 871-885, 2001.

Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq. Bras. Cardiol. 109(2Supl.1): 1-76, 2017.

Ferrari F, Stein R, Motta MT, Moriguchi EH. PCSK9 inhibitors: clinical relevance, molecular mechanisms and safety in clinical practice. Arq Bras Cardiol. 112(4): 453-460, 2019.

Fiorucci S, Mencarelli A, Palladino G, Sipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 30(11): 570-580, 2009.

Garcia MJ, Reinoso RF, Sanchez-Navarro A, Prous JR. Clinical pharmacology of statins. Methods Find. Exp. Clin. Pharmacol. 25(6): 457-481, 2003.

Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). PNAS. 102(23): 8132–8137, 2005.

Ge L, Wang J, Qi W, Miao H, Cao J, Qu Y, Li B, Song B. The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1. Cell Metab. 7(6): 508-519, 2008.

Glueck CJ, Ford SJ, Scheel D, Steiner P. Colestipol and cholestyramine resin: comparative effects in familial type II hyperlipoproteinemia. JAMA. 222(6): 676-681, 1972.

Gotto AM. Statin therapy: Where are we? Where do we go next? Am J. Cardiol. 87(5A): 13B-18B, 2001.

Haines BE, Wiest O, Stauffacher CV. The Increasingly complex mechanism of HMG-CoA reductase. Accounts of chemical research. 46(11): 2416-2426, 2012.

Hajar R. Statins: Past and Present. History of Medicine, Heart Views. 12(3): 121-127, 2011.

Hajar R. PSCK9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views. 20(2): 74-75, 2019.

Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 19(1): 26-37, 1998.

Harrold M. Antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis. In: Lemke TL, Williams DA (Org.). Foye’s Principles of Medicinal Chemistry. 7 ed. Baltimore: Lippincott Williamns & Wilkins, 2013, p. 815-410.

Heel RG, Brogden RN, Pakes GE, Speight TM, Avery GS. Colestipol: a review of its pharmacological proprieties and therapeutic efficacy in patients with hypercholesterolemia. Drugs. 19(3): 161-180, 1980.

Ishikawa Y, Itoh T, Satoh M, Fusazaki T, Sugawara S, Nakajima S, Nakamura M, Yoshihiro M. Impact of water and Lipid-Soluble statins on nonculprit lesions in patients with acute coronary syndrome. Int Heart J. 59(1): 27-34, 2018.

Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292: 1160-1664, 2001.

Jain KS, Kathiraven MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg. Med. Chem. 15(14): 4674-4699, 2007.

Jia L, Betters J, Yu L. Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport. Annu. Rev. Fisiol. 73: 239-259, 2011.

Johns WH, Bates TR. Quantification of the Binding Tendencies of Cholestyramine I: Effect of Structure and Added Electrolytes on the Binding of Unconjugated and Conjugated Bile-Salt Anions. J Pharm Sci. 58(2): 179-183, 1969.

Karaki F, Ohgane K, Dodo K, Hashimoto Y. Structure–activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect. Bioorg. Med. Chem. 21(17): 5297-5309, 2013.

Kastelein J, van Dam MJ. A new role for combination therapy in lipid management. Brit J Cardiol. 8(11): 639-653, 2001.

Kawashiri MA, Higashikata T, Nohara A, Kobayashi J, Inazu A, Koizumi J et al. Efficacy of colestimide administered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ. J. 69(5): 515-520, 2005.

Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 44(5) 467-494, 2005.

Krause MP, Hallage T, Gama MP, Sasaki JE, Miculis CP, Buzzachera CF, Silva SG. Associação entre perfil lipídico e adiposidade corporal em mulheres com mais de 60 anos de idade. Arq Bras Cardiol. 89(3): 163-169, 2007.

Lammert F, Wang DQ. New Insights into the Genetic Regulation of Intestinal Cholesterol Absorption. Gastroenterology. 129: 718–734, 2005.

Magalhães MEC. Mecanismos de rabdomiólise com as estatinas. Arq. Bras. Cardiol. 85(Suppl. 5): 42-44, 2005.

Manniello M, Pisano M. Alirocumab (Praluent): first in the new class of PSCK9 inhibitors. P T. 41(1): 28-53, 2016.

McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 4(1): 9-14, 2003.

Moghadasan M. Clinical pharmacology of 3-hidroxy-3-metylglutaryl coenzyme-A reductase inhibitors. Life Sci. 65(13): 1329-1337, 1999.

Nadruz Junior W. Diagnóstico e tratamento de fatores de risco. Com Ciência. 109: 2009.

Page MM, Watts GF. PCSK9 inhibitors – mechanism of action. Aust. Prescr. 39(5): 164-167, 2016.

Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 30(4): 430-437, 2002.

Pereira DG. Importância do metabolismo no planejamento de fármacos. Quim. Nova. 30(1): 171-177, 2007.

Pfefferkorn JA, Canção Y, Sun K, Miller SR, Trivedi BK, Choi C, et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 17(16): 4538-4544, 2007.

Raydan SSS. Estudo retrospectivo da incidência de fatores de risco em portadores da doença arterial coronariana. Braz. J. Hea. Rev. 2(3): 1848–1917, 2019.

Reiss AB, Shah N, Muhieddine D, Zhen J, Yudkevich J, Kasselman LJ et al. PSCK9 in cholesterol metabolism: from bench to bedside. Clin Sci. 132(11): 1135-1153, 2018.

Roche VF. Antihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lesson. Am. J. Pharm. Educ. 69(4): 546-560, 2005.

Rosenblum SB, Huynh T, Afonso A, Davis HR, Yumibe N, Clader JW, Burnett DA. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41(6): 973-980, 1998.

Salisburry BG, Davis HR, Burrier RE, Burnett DA, Boykow G, Caplen MA et al. Hypercholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis, 115(1): 45-63, 1995.

Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an updates. Fundam. Clin. Pharmacol. 19(1): 117-125, 2005.

Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. PNAS. 100(3): 928-933, 2003.

Sliskovic DR, Picard JA, Krause BR. ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog. Med. Chem. 39: 121-171, 2002.

Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action. Pharmacol. Ther. 175: 1-16, 2017.

Stein EA. The power of statins: aggressive lipid lowering. Clin. Cardiol. 26(4 Suppl 3): III25-31, 2003.

Stossel TP. The Discovery of Statins. Cell. 134(6): 903-905, 2008.

Suzuki T, Oba K, Igari Y, Watanabe K, Matsumura N, Futami-Suda S et al. Effects of bile-acid-binding resin (colestimide) a blood glucose and visceral fat in patients with type II diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. J. Diabetes Complications. 26(1): 34-39, 2012.

Tavori H, Melone M, Rashid S. Alirocumab: PSCK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 12(10): 1137-1144, 2014.

Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2(7): 517-26, 2003.

Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann. Pharmacother. 44: 507-514, 2010.

Yadav K, Sharma M, Ferdinand KC. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Present Perspectives and Future Horizons. Nutr Metab Cardiovasc Dis. 26(10): 853-862, 2016.

Yu L. The structure and function of Niemann–Pick C1-like 1 protein. Curr. Opin. Lipidol. 19(3): 263-269, 2008.




DOI: https://doi.org/10.34119/bjhrv3n4-143

Refbacks

  • There are currently no refbacks.